PRME

Prime Medicine, Inc.

Biotechnology · Biotechnology

$55.69 sample

+0.33 (+0.60%) 1D

Market cap

$235.0B

Price as of

2026-10-15

Latest filing

8-K · 2026-09-22

Alerts

8

Price$55.69 +7.51% 3M daily closessample

55.6951.23

2026-07-202026-08-112026-09-022026-09-232026-10-15

purchase / approvalsale / rejectionfiling / neutral

Latest events

Filings, trades, FDA; newest first

Oct 09INSInsider buy: 10% owner
Sep 30INSInsider buy: EVP, Operations
Sep 22SEC8-K filed: material event
Sep 17INSInsider sell: Chief Financial Officer
Sep 09SEC10-Q filed
Aug 31SECForm 144 filed
Aug 21INSInsider sell: Chief Executive Officer
Aug 13SEC10-Q filed

Sign up to see the real PRME record →

Company facts

SEC EDGAR registration

Name: Prime Medicine, Inc.
Sector: Biotechnology
Industry: Biotechnology
Smart-money score: +48sample, -100 to +100
Reporting currency: USD

Who is positioning in PRME

sample

Insiders: 12 insider transactions over 90 days, net selling, $24.9M
Congress: 3 members traded over 90 days
Institutions · 13F: 15 funds hold $4.1B
Activists · 13D/G: No 13D/13G activist filings on record

How are the fundamentals trending?

sample, by period end

Revenue$8.3B +22.4% y/y

Q4 2024Q3 2026

Inventory$4.8B +7.5% y/y

Q4 2024Q3 2026

Accounts receivable$3.5B +6.8% y/y

Q4 2024Q3 2026

Total debt$9.9B +19.1% y/y

Q4 2024Q3 2026

Peers

sample

Sample peer A: $142.0B -8.4% 3M
Sample peer B: $64.5B -1.2% 3M
Sample peer C: $167.8B +10.7% 3M
Sample peer D: $49.0B +6.6% 3M
Sample peer E: $200.7B -6.7% 3M